Sanofi-Aventis: New data show enoxaparin reduces risk of repeat heart attacks, stroke in some patients

By E. Janene Geiss

Philadelphia, Sept. 5 - Sanofi-Aventis said Monday that results of its percutaneous coronary intervention-Extract-TIMI 25 study showed that among patients with myocardial infarction who initially received fibrinolytic therapy and adjunctive antithrombotic therapy with either enoxaparin or unfractionated heparin and subsequently underwent percutaneous coronary intervention, the enoxaparin strategy reduced the risk of death or recurrent heart attacks.

Fewer patients in the enoxaparin group had to undergo percutaneous coronary intervention compared to those in the unfractionated heparin group, according to a company news release.

These advantages of enoxaparin were observed during the treatment phase before percutaneous coronary intervention and this benefit persisted after percutaneous coronary intervention for up to 30 days without an increase in risk of major bleeding between the enoxaparin and unfractionated heparin groups, officials from the Paris-based pharmaceutical company said.

The results were presented at the World Congress of Cardiology meeting in Barcelona.

The aim of the study was to determine whether enoxaparin was associated with superior efficacy and safety compared to unfractionated heparin in the percutaneous coronary intervention setting.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.